USANA Health Sciences, Inc. (USNA) AI Stock Analysis

USANA Health Sciences, Inc. is a developer and distributor of evidence-based nutritional and personal care products. Founded in 1992 and based in Salt Lake City, Utah, the company offers nutritional essentials such as CellSentials, along with optimizers targeting cardiovascular and digestive health, and meal replacement shakes and snack bars. Its skincare line, Celavive, addresses diverse skin types and ethnicities. USANA distributes products through direct sales associates and e-commerce platforms across the Asia Pacific, the Americas, and Europe, providing business-building resources and marketing tools. It also maintains research partnerships with Beijing University of Chinese Medicine and the National Sports Training Bureau.

Between FY2021 and FY2025, revenue contracted at a 5-year CAGR of -4.0%. Annual sales fell from $1.19B in FY2021 to $854.5M in FY2024, before rising 8.3% to $925.3M in FY2025. Over the same period, gross margin tightened from 81.6% to 78.3%, operating margin dropped from 14.3% to 5.5%, and net income fell from $116.5M to $10.8M. For the trailing twelve months, revenue was $913.4M with a net profit margin of -2.4% and an operating margin of 4.1%. In the latest quarter ended June 30, 2026, quarterly revenue declined 5.3% year-over-year, while quarterly earnings fell 16.6%.

As of June 30, 2026, USANA held $168.6M in cash and short-term investments, with total assets of $703.2M and shareholders' equity of $526.3M. Its current ratio stood at 2.66. In FY2025, the business generated $22.3M in operating cash flow and $8.5M in free cash flow, representing a decline from $108.5M of free cash flow in FY2021. Capital expenditures were $13.8M in FY2025, and the company spent $27.5M on share buybacks, contributing to a 5-year share count change of -6.0%.

USANA's market capitalization is $287.1M, with an enterprise value of $110.7M. The stock trades at a forward P/E of 7.9x, an EV/EBITDA of 2.6x, and a price-to-sales multiple of 0.3x. These levels are below the median of its US-listed Consumer Defensive peers, which reflect a forward P/E of 14.3x, an EV/EBITDA of 11.7x, and a price-to-sales of 0.7x. The company's price-to-book ratio is 0.5x, and its PEG ratio is 0.66. Over the past year, USNA returned -26.2% versus 16.8% for the S&P 500 (SPY), and its 5-year return stands at -84.3% compared to 83.0% for the index.

Wall Street coverage includes 1 analyst for the next fiscal year with a mean price target of $25.00, which is 60.9% above the last close of $15.54. For the current fiscal year ending December 31, 2026, estimated EPS is $0.76 (a 60.6% decline) on estimated revenue of $909.0M. For the next fiscal year, projected EPS is $1.77 on revenue of $945.0M. Over the last four quarters, USANA beat EPS estimates 2 times. The next earnings date is November 3, 2026.

This page is an AI-written research summary of USANA Health Sciences, Inc. (USNA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: USNA income statement, USNA balance sheet, USNA key metrics, USNA analyst forecast, USNA chart. See the USNA stock overview for the latest quote and news.